Skip to main content
. Author manuscript; available in PMC: 2018 Aug 17.
Published in final edited form as: Nature. 2018 Jan 24;554(7690):62–68. doi: 10.1038/nature25459

Figure 4. Defined allelic states and/or combinations of hallmark PDAC tumor-suppressor alterations license oncogenic dosage variation.

Figure 4

Types and frequencies of KrasG12D gene dosage gains and Cdkn2a inactivations, defined by aCGH and amplicon-based KrasG12D sequencing in PDAC mouse models expressing pancreas-specific KrasG12D alone (PK) or in combination with engineered Cdkn2aΔHOM (PKC), Trp53ΔHOM (PKP) or Tgfbr2ΔHET/HOM (PKT) inactivation.